Analyst: J&J may need a $10B-plus deal

Will Johnson & Johnson ($JNJ) have to look outside for growth? That's the conclusion of one analyst, who says the company may look at deals worth more than $10 billion to compensate for a lack of organic growth and to provide an outlet for its steady buildup of cash.

In a note to investors, Morgan Stanley's David Lewis says J&J may be looking at consumer deals outside the U.S., along with buys in medical devices and diagnostics. And as Bloomberg points out, the company had a $27.7 billion stash of cash and short-term investments at the end of 2010--ample capital for a shopping foray.

Plus, J&J's 2010 results weren't so hot; sales were mostly stagnant at $61.6 billion after a year of recalls and other manufacturing troubles within its consumer health unit. "J&J's lackluster organic growth, limited leverage opportunities and growing cash hoard increasingly point to the possibility" that the company would be shopping for bigger deals, Lewis says. "A large acquisition ($10+ billion) may be a preferred avenue to bolster J&J's growth profile."

The company wouldn't comment. But dealmaking certainly isn't foreign to J&J, which has steadily added to its confederation of operating companies. Over the past five years, J&J has announced 52 deals with an average size of $669 million; its biggest recent deal was the $16.6 billion buyout of Pfizer's consumer health business in 2006, Bloomberg notes.

- see an excerpt from Lewis' investor note
- read the story from Bloomberg
- get more from American Banking News

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.